Fresenius Group Overview

Results Center

To archive

FY/19 Results

Fresenius reports 16th consecutive record year Significant investments into growth – Healthy growth for 2020 expected – Medium-term growth targets confirmed
  • Good organic sales growth across all business segments

  • Fresenius Kabi’s excellent Emerging Markets growth partially offsets softer development in North America

  • Fresenius Helios shows continued stabilization in Germany and strong growth in Spain

  • Fresenius Medical Care expects to show strong growth in 2020

  • 27th consecutive dividend increase proposed

Selected Key Figures FY/19

key figures FY 19

1 On a comparable basis

2 In constant currency

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA